Загрузка...
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Crizotinib was the first approved ALK inhibitor with significant benefits over chemotherapy. However, patients inevitably develop di...
Сохранить в:
| Опубликовано в: : | Lung Cancer (Auckl) |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5648304/ https://ncbi.nlm.nih.gov/pubmed/29075144 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S126507 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|